Galapagos NV (GLPG) has been beaten down lately with too much selling pressure. While the stock has lost 21.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator t ...

Photo by JONAS ROOSENS / BELGA MAG / Belga via AFP) (Photo by JONAS ROOSENS/BELGA MAG/AFP via Getty ... [+] Images)BELGA MAG/AFP via Getty ImagesDeal OverviewOn January 8, 2025, Galapagos NV. (US Nasdaq ADR: GLPG; $23.76, Market Capitalization: $1.56 billion), announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on innovative medicines. The SpinCo will be focused on building a pipeline of innovative medicines with robust clinical proof-of-concept in oncolo ...

Strategic Reorganization and Separation - Galapagos plans to separate into two entities: Galapagos, focusing on cell therapy leadership in oncology, and SpinCo, dedicated to building a pipeline of innovative medicines through transformational transactions [1][4] - SpinCo will be capitalized with approximately €2.45 billion in cash and will focus on oncology, immunology, and virology through strategic business development transactions [4] - Galapagos will gain full global development and commercialization rights to its pipeline, subject to single-digit royalties to Gilead on net sales of certain products [2][5] Corporate Structure and Shareholder Impact - Gilead will hold approximately 25% of the outstanding shares in both Galapagos and SpinCo post-separation, with lock-up periods until March 31, 2027, for Galapagos and six months for SpinCo [7] - All Galapagos shareholders will receive shares of SpinCo on a pro rata basis based on their holdings as of a record date [6] - Gilead will nominate two Directors to the SpinCo Board, which will be majority independent [7] Financial and Operational Focus - Galapagos expects its normalized annual cash burn to be between €175 million and €225 million post-reorganization, excluding restructuring costs [12] - The company plans to discontinue its small molecule discovery programs and seek partners for its small molecule assets, including the TYK2 inhibitor GLPG3667 [10] - Galapagos will reduce approximately 300 positions, representing 40% of its workforce, primarily in Europe, to focus on long-term value creation in cell therapy [11] Strategic Vision and Leadership - The separation aims to unlock shareholder value by allowing Galapagos to focus on cell therapy in oncology while SpinCo pursues innovative therapies through strategic transactions [3][8] - Galapagos' lead CAR-T candidate, GLPG5101, has shown encouraging efficacy and safety in relapsed/refractory non-Hodgkin lymphoma, supporting its decentralized cell therapy manufacturing platform [9] - The reorganization is expected to position Galapagos for sustainable growth and future success in cell therapies [13] Transaction Process and Timeline - The separation is subject to customary conditions, including consultations with works councils and shareholder approval, with completion expected by mid-2025 [15] - Goldman Sachs International and Lazard acted as financial advisors, while Baker McKenzie and Allen Overy Shearman Sterling provided legal counsel [16] Industry and Market Implications - The separation allows investors to assess the distinct value propositions of Galapagos and SpinCo, enabling targeted investment strategies based on each entity's focus [14] - SpinCo's focus on innovative medicines and strategic transactions aligns with emerging trends in biotechnology and high unmet medical needs [4][8]

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Gala ...

Q3 2024 Financial Results October 31, 2024 Galápagos Disclaimer this presentation contains "forward-looking statements", all of which involve certain risks and unertainties. Thees statements are often, but are not always, made through t fbeleve," "expect","nerl," "upcoming"," thune," "encouraging," tim," "con," "could," "potential," "forward," "hiend," "hney"," might," "potential," "will," "towards," "onti rongress," reenaint," tecnolor," fluther and "predict", or similar expressions. There statements inclu ...

Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO & COO Jeevan Shetty - Head of Development Oncology Wulf Bocher - Head Immunology Therapeutic Area Conference Call Participants Xian Deng - UBS Judah Frommer - Morgan Stanley Alexander Kelly - TD Cowen Shan Hama - Jefferies Nevin Varghese - RBC Capital Markets Jacob Mekhael - KBC Securities Faisal Khurshid - Leeri ...

EXHIBIT 99.1 Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in onco ...

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Inves ...

Board Appointment - Oleg Nodelman appointed as Non-Executive Non-Independent Director to Galapagos' Board of Directors, effective October 7, 2024 [1] - Mr Nodelman replaces Dan G Baker who stepped down on October 6, 2024 [2] - Mr Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm [3] - Mr Nodelman holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University [4] Strategic Impact - The addition of Mr Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on the Forward, Faster strategy to accelerate innovation and create near-and long-term value [2] - Mr Nodelman's deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping the company execute its near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers [3] - Mr Nodelman brings a wealth of experience in driving shareholder value, strategic transformations, and long-term growth initiatives [3] Company Overview - Galapagos is a biotechnology company with operations in Europe and the US dedicated to transforming patient outcomes through life-changing science and innovation [6] - The company focuses on high unmet medical needs and synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology [6] - Galapagos has capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, and the financial strength to invest strategically for the long-term [6]

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified that EcoR1 Capital LLC holds 6,713,553 of Galapagos' voting rights, consisting of 839,388 ordinary shares and 5,874,165 American Depository Receipts, further ...